Related Experiment Video
Updated: Dec 30, 2025
In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
Identification of genes associated with SiHa cell sensitivity to paclitaxel by CRISPR-Cas9 knockout screening
1Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University Beijing 100006, China.
Abstract:
Although chemotherapy has significantly improved the prognosis of patients with cervical cancer, many patients exhibit selective responses to chemotherapy. This study aimed to identify genes associated with the sensitivity of cervical cancer cells to paclitaxel. SiHa cells were transfected with lentiCRISPR (genome-scale CRISPR knockout library v.2) and then treated with paclitaxel or vehicle for 14 days. Subsequently, we screened for candidate genes whose loss resulted in sensitivity to paclitaxel. We obtained 374 candidates, some of which were consistent with those reported in previous studies, including ABCC9, IL37, EIF3C, AKT1S1, and several members of the PPP gene family (PPP1R7, PPP2R5B, PPP1R7, and PPP1R11). Importantly, our findings highlighted the newly identified genes that could provide novel insights into the mechanisms of paclitaxel sensitivity in cervical cancer. Cas9 technology provides a reliable method for the exploration of more effective combination chemotherapies for patients at the gene level.
Insights
Researchers identified 374 genes influencing cervical cancer cell sensitivity to paclitaxel chemotherapy. This discovery aids in understanding treatment response and developing targeted therapies.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Cervical cancer treatment relies on chemotherapy, but patient responses vary.
- Identifying genetic factors influencing chemotherapy sensitivity is crucial for personalized medicine.
Purpose of the Study:
- To identify genes associated with paclitaxel sensitivity in cervical cancer cells.
- To explore novel genetic targets for improving chemotherapy efficacy.
Main Methods:
- Utilized lentiCRISPR (genome-scale CRISPR knockout library v.2) for gene screening in SiHa cervical cancer cells.
- Treated cells with paclitaxel and analyzed gene knockouts affecting drug sensitivity.
- Employed Cas9 technology for large-scale genetic screening.
Main Results:
- Identified 374 candidate genes influencing paclitaxel sensitivity.
- Confirmed known genes (e.g., ABCC9, IL37, EIF3C, AKT1S1, PPP family members) and discovered novel candidates.
- Demonstrated Cas9 technology's utility in gene-level chemotherapy research.
Conclusions:
- The study identified novel genes impacting paclitaxel sensitivity in cervical cancer.
- Findings offer new insights into the mechanisms of chemotherapy response.
- Cas9 technology facilitates the exploration of gene-level targets for enhanced combination chemotherapies.
